A total of 161 patients with chronic hepatitis B refractory to to combined therapy with lamivudine ( LAM ) and ADV were randomized to receive INF-2b monotherapy ( 510 ( 6 ) , three times a week ) ( group A ) or combined therapy with entecavir ( 0.5 mg/day ) plus adefovir ( 10 mg/day ) ( group B ) .